Please complete Pre-test

Chapter 2 of 5



Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

Evolving Paradigms in AML: Navigating New Therapeutic Opportunities in the Frontline and Relapsed Settings is a digitally captured archive of a live independent satellite symposium held on September 13 during the SOHO 2018 Meeting. The medical landscape of AML continues to evolve, as evidenced by the approval of five new agents since April 2017 and the anticipated approval of additional novel agents in the very near future. An explosion of clinical trials and updated practice guidelines – coupled with a multitude of therapies in late-stage development – has created the vast challenge of staying up-to-date with clinical evidence impacting practice and patient outcomes. Our experts provide a high-level overview of the latest data from newly diagnosed to relapsed disease, focusing on the most current therapeutic landscape.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, nurses, pharmacists and other allied healthcare professionals who provide care to patients with acute myeloid leukemia.

Learning Objectives

Upon completion of this educational activity, participants should be able to:
  • Summarize key considerations which drive the clinical decision-making process in newly diagnosed versus relapsed/refractory AML
  • Identify issues requiring special consideration in older AML patients and patients with high-risk disease
  • Outline practical strategies for effectively incorporating new and recently approved agents and combination regimens for AML into clinical practice, including treatment selection, dosing, and adverse event management
  • Identify key clinical trial information which may further impact clinical practice in AML in the future


Chapter 1: Overview: The Expanding Treatment Paradigm in AML – Farhad Ravandi, MD

Chapter 2: FLT3 Mutations in AML: Navigating the New and Emerging Therapeutic Options – Richard Stone, MD

Chapter 3: High-Risk AML: New Therapeutic Option and Trials in Progress – Guillermo Garcia-Manero, MD

Chapter 4: Recent Developments and Current Status of Immunotherapy in AML – Naval Daver, MD

Chapter 5: The Impact of New and Emerging IDH Inhibitors on Clinical Practice – Farhad Ravandi, MD

Instructions for Participation and Credit

This activity is eligible for credit through October 12, 2019. After this date, this activity will expire and no further credit will be awarded.
1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biographies

Naval Daver, MD
Associate Professor
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Dr. Naval Daver received his medical degree from Grant Medical College and Sir JJ Group of Hospitals, Mumbai, India, followed by a residency and fellowship in hematology-oncology from Baylor College of Medicine in Houston, Texas. He is an Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center.

A clinical investigator with a focus on molecular and immune therapies in acute myeloid leukemia (AML) and myelofibrosis, Dr. Daver is the co/principal investigator for more than 25 ongoing clinical trials in these diseases. These trials focus on developing a personalized therapy approach by targeting specific mutations or immune pathways expressed by patients with AML, evaluating novel combinations of targeted, immune and cytotoxic agents, and identifying and overcoming mechanism of resistance. He is especially interested in developing immune checkpoint- and vaccine-based approaches in AML, myelodysplastic syndromes (MDS), and myelofibrosis, and is conducting a number of these trials. Dr. Daver has published more than 100 peer-reviewed manuscripts. He has also authored numerous abstracts at national and international conferences.

Guillermo Garcia-Manero, MD
Chief, Section of Myelodysplastic Syndromes
Deputy Chair, Translational Research
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Dr. Guillermo Garcia-Manero received his medical degree from the University of Zaragoza, Spain. He completed his clinical internship, residency, and clinical fellowship in hematology and medical oncology at Thomas Jefferson University Hospital, Philadelphia. Dr. Garcia-Manero is Professor and Chief, Section of Myelodysplastic Syndromes (MDS) and Deputy Chair of Translational Research, Department of Leukemia, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center (UTMDACC) in Houston. In addition, he is Co-Director, DNA Methylation Core, and the endowed Dr. Kenneth B. McCredie Chair in Clinical Leukemia Research, Department of Leukemia, Division of Cancer Medicine, at UTMDACC.

Dr. Garcia-Manero is board certified in medical oncology (hematology eligible), and internal medicine. He holds membership in the American Association for the Advancement of Science, American Society of Hematology, American Society of Clinical Oncology, American Association of Cancer Research (Chair, Scientific Review Committee), Aplastic Anemia and International Myelodysplastic Syndromes Foundation (Steering Committee/Medical Advisory Board), American Medical Association (AMA) Foundation, Society of Hematologic Oncology, and the European Hematology Association. In addition, he is an editor/journal reviewer for numerous peer-reviewed publications. Dr. Garcia-Manero has written more than 800 abstracts, invited articles, and editorials in scientific journals, and is the Principal Investigator in several MDS studies.

Farhad Ravandi, MD
Professor, Department of Leukemia
Division of Cancer Medicine
Chief, Section of Developmental Therapeutics
The University of Texas MD Anderson Cancer Center
Houston, Texas

Dr. Farhad Ravandi received his medical degree from St. Mary's Hospital Medical School/Imperial College, University of London. He completed clinical residencies in internal medicine at The University of Texas, and in hematology at Baylor College of Medicine. He also completed a clinical fellowship in hematology/oncology, and a fellowship in blood and marrow transplantation, hematology/stem cell transplantation at The University of Texas MD Anderson Cancer Center. Dr. Ravandi is a Professor in the Department of Leukemia, Division of Cancer Medicine, and Chief, Section of Developmental Therapeutics at The University of Texas MD Anderson Cancer Center.

Dr. Ravandi holds board certification in internal medicine, medical oncology, and hematology. He is a member of the Southwest Oncology Group Leukemia Committee, the NCCN Acute Myeloid Leukemia Committee, the International Hairy Cell Leukemia Consortium, and the Cancer and Leukemia Group B Data Safety Monitoring Board. Dr. Ravandi is actively involved in clinical and translational research for the treatment of patients with various hematologic malignancies, in particular leukemias. He has extensively published his clinical research results in the field of adult leukemias, with a focus on acute leukemias in numerous peer-reviewed publications, articles, editorials, abstracts, and books/book chapters.

Richard Stone, MD
Professor of Medicine
Harvard Medical School
Chief of Staff
Director, Adult Acute Leukemia Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Dr. Richard Stone received his medical degree from Harvard Medical School, Boston. He completed his internal medicine residency training at Brigham and Women’s Hospital and his hematology-oncology fellowship at Dana-Farber Cancer Institute. He is the Chief of Staff and Director of the Adult Acute Leukemia Program at Dana-Farber, and Professor of Medicine at Harvard Medical School. Dr. Stone is nationally recognized for his translational and clinical research concerning blood and bone marrow malignancies including acute leukemia, myeloproliferative disorders, and myelodysplastic syndrome (a bone marrow failure state that may convert to leukemia).

In addition to his work at Dana-Farber, Dr. Stone serves as Chair of the Medical Oncology Board of the Aplastic Anemia & MDS International Foundation and Chairman of the Leukemia Core Committee for the National Cooperative Trials Group the Alliance.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at

Provided by MediCom Worldwide, Inc.

This activity is supported by educational grants from Agios Pharmaceuticals, Inc., Daiichi Sankyo, Inc., Helsinn Healthcare SA, and Jazz Pharmaceuticals

©2018 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-18-035-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 18-035-084


As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures

Dr. Naval Daver has received honoraria related to formal advisory activities from AbbVie Inc., Agios, Astellas Pharma US, Inc., Bristol-Myers Squibb Company, Daiichi Sankyo, Inc., Genentech, Inc., ImmunoGen, Inc., Incyte Corporation, Jazz Pharmaceuticals plc, Otsuka Pharmaceutical Co., Ltd., Novartis AG, Pfizer Inc., and SERVIER. He has received grant support related to research activities from AbbVie, Bristol-Myers Squibb, Daiichi Sankyo, Genentech, ImmunoGen, Incyte, Karyopharm Therapeutics, Nohla Therapeutics, Novartis, Pfizer, SERVIER, and Sunesis.

Dr. Guillermo Garcia-Manero has disclosed no relevant financial relationships.

Dr. Farhad Ravandi has received honoraria related to formal advisory activities and grant support related to research activities from Amgen Inc., Seattle Genetics, Inc., Sunesis Pharmaceuticals, Inc., and Xencor, in addition to grant support related to research activities from Bristol-Myers Squibb Company and Selvita.

Dr. Richard Stone has received honoraria as a consultant from AbbVie Inc., Agios, Amgen Inc., Arginex, Arog Pharmaceuticals, Inc., Astellas Pharma US, Inc., Celator Pharmaceuticals, Inc., Celgene Corporation, Cornerstone Therapeutics Inc., Fujifilm Corporation, Janssen Pharmaceuticals, Inc., Jazz Pharmaceuticals plc, Novartis AG, Orsenix, LLC, Otsuka Pharmaceutical Co., Ltd., and Pfizer Inc.; as well as honoraria related to formal advisory activities from Actinium Pharmaceuticals, Inc. He has received grant support related to research activities from Agios, Arog, and Novartis. He has also disclosed he is a steering committee and data safety monitoring board (DSMB) member of Celgene and board member of Actinium.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Kristin Burke, Project Manager, Keith D’Oria, Medical Writer, Joan Meyer, RN, MHA, Executive Director, and Bill Stoff, Director of Operations, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.